New Strategies Boost IL-12 Immunotherapy for Pancreatic Cancer

Pancreatic cancer is notoriously aggressive with poor prognosis, often resistant to conventional therapies. Immunotherapy holds promise, but its efficacy in pancreatic cancer has been limited, partly due to the highly immunosuppressive tumor microenvironment. Current approaches struggle to deliver potent immunomodulators like interleukin-12 (IL-12), a powerful cytokine that stimulates anti-tumor immune responses, effectively and safely to the tumor site, leaving a critical gap in how to harness its full therapeutic potential without systemic toxicity.

The review highlighted that localized delivery of IL-12 (interleukin-12), a potent cytokine that stimulates anti-tumor immune responses, significantly improved therapeutic outcomes compared to systemic administration. Across multiple preclinical studies, intratumoral Ad-IL-12 led to a 60-75% reduction in tumor volume and a 2.5-fold increase in CD8+ T cell infiltration compared to control groups (p<0.001). Furthermore, LNP-IL-12 formulations demonstrated a 40% increase in median survival time in murine models, extending it from 25 days in controls to 35 days (p<0.05), while also showing a 70% decrease in metastatic burden. The most promising strategies involved combining IL-12 delivery with checkpoint inhibitors, achieving complete tumor regression in 30% of treated animals and a 5-fold increase in overall survival compared to monotherapy. These advanced delivery methods also drastically reduced systemic toxicity, with IL-12 serum levels remaining below 100 pg/mL in targeted delivery groups, whereas systemic delivery often resulted in levels exceeding 500 pg/mL, leading to severe adverse events like cytokine storm.